Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Zyprexa

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Olanzapine-treated patients showed 49% improvement of manic symptoms on the Young-Mania Rating Scale compared to 38% improvement for patients treated with Abbott's Depakote (valproate) in a three-week, double-blind study of 251 hospitalized bipolar patients, the company said. Results of the trial, which was the first head-to-head study of the two agents, was presented at the 13th European College of Neuropsychopharmacology Congress in Munic
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001204

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel